Algeron

DRUG3 trials

Sponsors

Biocad

Conditions

HepatitisHepatitis CHepatitis C/ Human Immunodeficiency Virus Coinfection

Phase 2

Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C

CompletedNCT01740089

BiocadHepatitis, Hepatitis C

Start: 2011-11-30End: 2013-12-31Updated: 2015-08-18

Phase 3

An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C

CompletedNCT01889433

BiocadHepatitis, Hepatitis C

Start: 2013-07-10End: 2015-12-02Updated: 2018-07-16

An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

CompletedNCT02103439

BiocadHepatitis, Hepatitis C, Hepatitis C/ Human Immunodeficiency Virus Coinfection

Start: 2013-06-06End: 2015-08-26Updated: 2018-08-09